Table 1.

Clinical and pathologic features by tumor B7-H4 expression

FeatureTumor B7-H4 expression, n (%)P
Negative, n = 106Positive, n = 153
Age at surgery, years
    <6555 (51.9)81 (52.9)0.867
    ≥6551 (48.1)72 (47.1)
Sex
    Female40 (37.7)45 (29.4)0.161
    Male66 (62.3)108 (70.6)
Symptoms at presentation49 (46.2)86 (56.2)0.114
Constitutional symptoms at     presentation9 (8.5)31 (20.3)0.010
Primary tumor size, cm
    <554 (50.9)48 (31.4)<0.001
    5 to <725 (23.6)28 (18.3)
    7 to <1012 (11.3)35 (22.9)
    ≥1015 (14.2)42 (27.5)
2002 primary tumor     classification
    pT1a41 (38.7)40 (26.1)0.012
    pT1b32 (30.2)29 (19.0)
    pT211 (10.4)28 (18.3)
    pT3a10 (9.4)18 (11.8)
    pT3b11 (10.4)32 (20.9)
    pT3c1 (0.9)4 (2.6)
    pT40 (0.0)2 (1.3)
Regional lymph node     involvement
    pNX/pN0105 (99.1)139 (90.9)0.005
    pN1/pN21 (0.9)14 (9.1)
Distant metastases at     nephrectomy
    pM091 (85.9)128 (83.7)0.632
    pM115 (14.1)25 (16.3)
2002 TNM stage groupings
    I69 (65.1)68 (44.4)0.006
    II10 (9.4)20 (13.1)
    III12 (11.3)39 (25.5)
    IV15 (14.2)26 (17.0)
Nuclear grade
    17 (6.6)6 (3.9)<0.001
    253 (50.0)33 (21.6)
    342 (39.6)89 (58.2)
    44 (3.8)25 (16.3)
Coagulative tumor necrosis16 (15.1)57 (37.3)<0.001
Sarcomatoid differentiation1 (0.9)7 (4.6)0.094
Lymphocytic infiltration
    Absent55 (51.9)44 (28.8)<0.001
    Focal37 (34.9)47 (30.7)
    Moderate11 (10.4)43 (28.1)
    Marked3 (2.8)19 (12.4)